Compare Hims and Hers Health Inc (HIMS) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Nomura Holdings Inc — how do they compare? Hims and Hers Health Inc trades at $30.87 (market cap $6.55B), while Nomura Holdings Inc trades at $9.61 (market cap $27.55B). The key difference: Nomura Holdings Inc is far larger — about 4.2× Hims and Hers Health Inc's market cap, and Nomura Holdings Inc pays a 3.4% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Nomura Holdings Inc for 55 Days on average.
| HIMS | NMR | |
|---|---|---|
Market Cap | $6.55B | $27.55B |
Volume | 14,842,814 | 782,470 |
Sector | Health | Financials |
52-Week High | $62.76 | $10.86 |
52-Week Low | $14.52 | $6.73 |
Typical Hold Time | 21 Days | 55 Days |
Enterprise Value | $7.25B | $38.54T |
Dividend Yield | — | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $30.92, up 4.67% on the day, amid a bearish technical signal and significant legal headwinds from multiple securities class action lawsuits. The stock shows mixed fundamentals with strong revenue growth to $2.35 billion in 2025 but a sharp reversal to a net loss of -$142 million in 2026, reflecting profitability challenges. Valuation ratios appear elevated with a P/E of 57.14 and EV/EBITDA of 205.86, while analyst consensus remains cautiously optimistic with a $32.17 price target.
The outlook is clouded by legal risks and recent earnings misses, though the company's gross margin of 68.43% indicates underlying business strength. Investment opportunity hinges on resolving regulatory scrutiny and returning to profitability, but near-term volatility is likely. Key risks include the FTC lawsuit outcome and sustained negative cash flow, demanding careful risk assessment by investors.
Nomura Holdings (NMR) trades at $9.59, up 0.63% with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with revenue growth from $1.66T to $1.98T projected for 2026, net income margin of 20.4%, and attractive valuation ratios including P/E of 11.33. Recent news highlights technical pattern recognition and inclusion on Zacks Strong Buy lists, though cash flow trends show operational challenges.
NMR presents a mixed outlook with undervalued fundamentals against bearish technicals. Investment opportunity lies in discounted valuation and earnings momentum, but risks include negative operating cash flows, rising debt-to-asset ratios, and inconsistent earnings performance. Analyst consensus leans cautious with 67% hold ratings despite recent positive coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
